Investigation of IOP reduction efficacy of Travoprost Ophthalmic Solution in patients with normal tension glaucoma - Investigation of IOP reduction efficacy of Travoprost Ophthalmic Solution in patients with normal tension glaucoma

Alcon Japan Ltd0 个研究点目标入组 34 人开始时间: 2013年9月2日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Pregnant women, lactating women or women who wish pregnancy during the study period. 2.A subject with Angle Grade in Shaffer classification 2 or less 3.Subjects whose glaucoma may be advanced and serious (less than -12 dB in MD). 4.Subjects who have complicated chronic or recurrent uveitis, scleritis or corneal herpes. 5.Subjects who have a history of ocular trauma, intraocular surgery or laser surgery for the included eye. 6.Subjects with ocular-infection and severe ocular complication. 7.Subjects whose BCVA is worse than 0.2. 8.Subjects who are difficult to conduct applanation tonometry for the included eye. 9.Subjects with known hypersensitivity to prostaglandin analogues or any ingredients used in the study. 10.Subjects who must use IOP lowering ophthalmic solutions other than Travatanz or oral carbonic anhydrase inhibitor (Diamox etc.) during the study period. 11.Subject who need any adrenocorticosteroids during the study period. 12.Subjects who received IOP lowering ophthalmic solution within the past 30 days. 13.Subjects whose doctors judged they are not suitable for the study participation.

发起方